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Abstract
Introduction: Secretory phospholipase A2 is supposed to play a role in acute lung injury but no data are available
for pediatric acute respiratory distress syndrome (ARDS). It is not clear which enzyme subtypes are secreted and
what the relationships are between enzyme activity, biophysical and biochemical parameters, and clinical
outcomes. We aimed to measure the enzyme and identify its subtypes and to study its biochemical and
biophysical effect. The secondary aim was to correlate enzyme activity with clinical outcome.
Methods: Bronchoalveolar lavage was performed in 24 infants with ARDS and 14 controls with no lung disease.
Samples were assayed for secretory phospholipase A2 and molecules related to its activity and expression. Western
blotting and captive bubble surfactometry were also performed. Clinical data were real time downloaded.
Results: Tumor necrosis factor-a (814 (506-2,499) vs. 287 (111-1,315) pg/mL; P = 0.04), enzyme activity (430 (253-
600) vs. 149 (61-387) IU/mL; P = 0.01), free fatty acids (4.3 (2.8-8.6) vs. 2 (0.8-4.6) mM; P = 0.026), and minimum
surface tension (25.6 ± 6.1 vs. 18 ± 1.8 mN/m; P = 0.006) were higher in ARDS than in controls. Phospholipids are
lower in ARDS than in controls (76.5 (54-100) vs. 1,094 (536-2,907) μg/mL; P = 0.0001). Three enzyme subtypes were
identified (-IIA, -V, -X), although in lower quantities in controls; another subtype (-IB) was mainly detected in ARDS.
Significant correlations exist between enzyme activity, free fatty acids (r = 0.823; P < 0.001), and surface tension
(r = 0.55; P < 0.028). Correlations also exist with intensive care stay (r = 0.54; P = 0.001), PRISM-III24 (r = 0.79; P<
0.001), duration of ventilation (r = 0.53; P = 0.002), and oxygen therapy (r = 0.54; P = 0.001).
Conclusions: Secretory phospholipase A2 activity is raised in pediatric ARDS and constituted of four subtypes.
Enzyme correlates with some inflammatory mediators, surface tension, and major clinical outcomes. Secretory
phospholipase A2 may be a clinically relevant target in pediatric ARDS.
Introduction
Secretory phospholipase A2 (sPLA2; EC: 3.1.1.4) belongs
to an ubiquitous enzyme superfamily, crucial for the
inflammation pathway [1]. In fact, sPLA2 releases free
fatty acids (FFA) from the sn-2 position of phospholipids,
producing arachidonic acid and its derivatives. Over 10
distinct sPLA2 isotypes carrying different substrate speci-
ficity have been described in mammalians and four of
these (sPLA2-IB, - IIA, -V, and -X) are expressed in total
lung extracts [2]. sPLA2s are relevant in lung physio-
pathology, since they may affect pulmonary function,
either producing inflammatory mediators or directly
catabolizing surfactant through the hydrolysis of its
phospholipids.
Previous studies have shown that the subtype -IIA of
sPLA2 is increased in broncho-alveolar lavage fluid
(BALF) in animal models of acute lung injury [3,4] and
sPLA2-IIA levels seem to correlate with clinical severity in
adults with acute respiratory distress syndrome (ARDS)
[5,6]. Other sPLA2 subtypes expressed in the lung have
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been suspected to play a role in ARDS, however their pre-
sence in human BALF has never been studied [2].
ARDS in infants differs from the syndrome in adults in
terms of epidemiology, triggering causes and prognosis
[7], thus requires specific additional research [8]. Since
sPLA2 is responsible for surfactant catabolism, its role is
even more important in this context. In fact, surfactant
replacement therapy has been tried, but it is not always
beneficial in all infants [9]. This may be due to the inacti-
vation by sPLA2, that creates a vicious cycle reducing
surfactant efficiency [10]. Interestingly, several sPLA2 inhi-
bitors carrying various specificities for sPLA2 subtypes, are
now becoming available [11]. In a preliminary study on
ARDS infants (conducted in 2007-2008), high levels of
sPLA2 and significant correlations with oxygenation
impairment and clinical severity have been found [12].
Thus, targeting sPLA2 could be an intriguing strategy for
ARDS, although a proof of concept of its clinical impor-
tance is still lacking.
This study was designed to fill this gap. Our main
purposes were: (1) to measure sPLA2 and the molecules
related to its expression and activity and to identify the
enzyme subtypes secreted into the alveoli; (2) to study
the biochemical and biophysical effects of sPLA2 in
BALF of infants with ARDS. The secondary aim was to
correlate sPLA2 levels with some clinical outcomes.
This study is a part of an international project investi-
gating the role of sPLA2 in various pediatric respiratory
diseases, whose plan has been described elsewhere [13].
Materials and methods
Patients
Eligible babies were all infants aged >30 days and ≤12
months admitted to our pediatric intensive care unit
(PICU) during 2011, diagnosed with ARDS, according to
the American-European criteria [14]. All babies were
subjected to echocardiography to exclude left atrial
hypertension and heart failure; no patient received ster-
oids. Controls fulfilled all the following criteria: (1) >30
days and ≤12 months of age; (2) intubation for reasons
other than any lung disease; (3) normal chest X-rays
and clinical examination; (4) PaO2/FiO2>300 or FiO2 =
0.21; (5) normal C-reactive protein; and (6) no respira-
tory diseases in the previous 3 months. Exclusion cri-
teria for both groups were: (1) need for thoracic surgery;
(2) congenital complex or lung malformations; and (3)
extracorporeal life support. Enrolment took place within
6 h from the fulfilling of ARDS criteria or from intuba-
tion (in controls). Participation to the study did not
modify in any way the routine clinical assistance: study
protocol was approved by the ethical committee of the
University Hospital ‘A. Gemelli’ and informed consent
was given by parents. Twenty-four cases and 14 controls
resulted eligible during the study and all were prospec-
tively enrolled: study population is described in Table 1.
Ventilation protocol
Infants were ventilated according to our formal routine
protocol that was unchanged during the study. Such
Table 1 Basic characteristics of study population.
ARDS group (n = 24) Control group (n = 14) P
Age (months) 4 (2-10.5) 6.5 (2-10.5) 0.457
Weight (Kg) 5.5 (4-10.8) 7 (4.8-9.6) 0.796
Male sex 13 (54.2) 8 (57.1) 0.643
PRISM-III24 16.5 (8.5-20.5) 3 (2-5.5) <0.001
Modified Murray’s score 5 (4.2-6) 0.75 (0.5-1.1) <0.001
PaO2/FiO2 127 (86-158) 510 (358-667) <0.001
OI 12.7 (9.9-18.5) 1.7 (1.2-2.2) <0.001
Crs (mL/cmH2O/kg) 0.35 (0.24-0.4) 0.9 (0.8-0.9) <0.001
Deaths 3 (12.5) 1 (7.1) 0.627
Co-morbidities Severe sepsis (5) Metabolic disease (1)
RSV infection (4) SAH (1)
H1N1 flu (4) Status epilepticus (2)
Aspiration (3) General anesthesia (10)
Smoke inhalation (4)
Trauma (2)
Late onset GBS infection (1)
Malignancy (1)
Data are expressed as median (interquartile range) or number (%). Murray’s score, PaO2/FiO2, OI and Crs are measured or calculated just before the
bronchoalveolar lavage. Co-morbidities indicate the ARDS etiology or the reasons for intubation in controls.
ARDS: acute respiratory distress syndrome; Crs: respiratory system static compliance; GBS: Group B streptococcus; HFOV: high frequency oscillatory ventilation; OI:
oxygenation index; RSV: respiratory sincitial virus; SAH: sub-arachnoid hemorrhage.
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protocol is reviewed every year and all physicians agreed
on it. Servo-I ventilators (Maquet, Solna, Sweden) and
cuffed endotracheal tubes were used to ventilate both
cases and controls. ARDS patients were ventilated using
pressure-controlled time-cycled modality, targeted at a
tidal volume (VT) of 6 mL/kg. Positive end-expiratory
pressure (PEEP) was set between 6 and 15 cmH2O and
FiO2 at the minimum level to obtain an arterial oxygen
saturation (SatO2) of 90-95%. PaCO2 values causing pH
>7.30 were allowed. Rescue high frequency oscillatory ven-
tilation (HFOV) was started according to our formal pro-
tocol [15]: in detail, HFOV is promptly instituted when a
plateau pressure ≤28 cmH2O did not allow to reach the
desired VT or when it was not possible to keep SatO2
>90%, with a FiO2 ≤0.6. Apnoeic sedation was provided
with remifentanil (0.1-0.2 g/Kg/min) and midazolam (1-2
g/Kg/min). After the acute phase, ARDS patients were
switched to pressure support ventilation when they had no
hemodynamic or temperature instability and fulfilled the
following criteria: mean airway pressure (Pāw) ≤15
cmH2O, FiO2 ≤0.5 with a SatO2 constantly >90% and no
desaturation >5%, while suctioning. Pressure support was
targeted to obtain VT of 6 mL/kg and stepped down as
long as the ARDS patient was improving. PEEP during
pressure support was set between 5 and 8 cmH2O; flow
trigger was set at the highest possible sensitivity without
auto-cycling; cycling-off was set at the 50% of the peak
inspiratory flow. ARDS patients were extubated to contin-
uous positive airway pressure at the same level of PEEP
(5-8 cmH2O). Extubation took place when they fulfil the
following criteria: (1) SatO2 ≥95% on PEEP ≤5 cm H2O
and FiO2 ≤50%; (2) minimal VT = 5 mL/kg; and (3)
respiratory rate appropriate for the age [16]. In the control
group, VT, PEEP, and FiO2 were 7-8 mL/kg, 4-5 cmH2O,
and <0.25, respectively.
Bronchoalveolar lavage
Non-bronchoscopic bronchoalveolar lavage was per-
formed within 6 h from the fulfilling of ARDS criteria in
patients or from the intubation in controls. Since this is a
part of our routine protocol for microbiological surveil-
lance, no procedure was done solely for the study
purposes. Lavage was performed as already described
[12] and following advices of the European Respiratory
Society Pediatric Task Force [17]. In detail, broncho-
alveolar lavage was performed by instillation of two
sequential aliquots of 1 mL/kg (up to a maximum of
5 mL) 0.9% NaCl warmed at 37°C, into the endotracheal
tube, followed by three respiratory cycles. A straight,
snub-nosed, end-hole suction catheter was gently
advanced into the endotracheal tube, while continuing
ventilation through a Y-connector. When resistance was
met, suctioning with 50 mmHg of negative pressure was
applied. The procedure was repeated with the infant’s
head turned 90° to the left and then to the right in order
to virtually ensure sampling from the right and the left
lung, respectively. The first collected fluid, reflecting
tracheo-bronchial milieu, was sent for microbiological
culture. The second aliquot consisted on average of 1.8 ±
0.5 mL (about 40% of the instilled volume) and was
diluted with 0.9% saline up to 2 mL and centrifuged
(3,000 rpm; 4°C; 10’). Cell-free supernatants were sepa-
rated, immediately frozen at -80°C and thawed only once
for the experiments. All samples were sterile and did not
show visible blood contamination.
sPLA2 assay and identification in BALF
BALF supernatants were centrifuged (12,000 rpm; 10’ and
then 3,500 rpm; 3’) through a membrane-filter with a
molecular weight cutoff of 30 kDa (Amicon Ultra; Milli-
pore, Billera, MA, USA), as previously published [18]. This
aims at separating secretory and cytosolic phospholipases
(which weigh approximately14 kDa and 80 kDa, respec-
tively [2]). sPLA2 total activity was then measured with a
non-radioactive method, as previously published [19].
Coefficient of variation and detection range were <5% and
5-80 IU/mL, respectively.
Different sPLA2 subtypes were identified by western
blotting, as follows. BALF samples were lyophilized after
trifluoroacetic acid treatment and 20 μg of their proteins
were resuspended in phosphate-buffered saline and
dye-sample loading buffer (50 mM Tris-HCl, pH 6.7; 10%
glycerol; 3% SDS; 1% b-mercaptoethanol; 0.01% bromo-
phenol blue). Samples were then boiled (100°C; 10’),
centrifuged (450g; 5’; 4°C) and then loaded into the gels.
Electrophoresis was performed using 12% SDS polyacrila-
mide and protein bands were later transferred into PVDF
membranes (Millipore - Billerica, MA, USA) by semi-dry
transfer system (Bio-Rad -Hercules, CA, USA), using stan-
dard protocols. After gentle shacking of 4 h in blocking
solution (5% non-fat dry milk, PBS, and 0.5% Tween 20),
blots were first incubated with anti-sPLA2-IB (polyclonal),
-V (monoclonal), or -X (polyclonal) antibodies (Santa-
Cruz Biotechnology, Santa Cruz, CA, USA). Anti-sPLA2-
IIA (monoclonal) antibody (Cayman Chemical, Ann
Arbor, MI, USA) was also used. All these antibodies were
specific for human phospholipases and were incubated in
blocking solution (1:200; 2 h). Every excess of primary
antibody was then removed twice using wash solution for
10’ and immune-reactive bands were subsequently incu-
bated with goat anti-mouse and anti-rabbit IgG-HRP sec-
ondary antibodies (1:2,000) in blocking solution for 1 h at
room temperature. Blots were washed four times for 10’
(each time) in PBS and 0.05% Tween 20 solution and
blotted proteins were revealed using Immobilon Western
Chemiluminescent HRP Substrate (Millipore, Billerica,
MA, USA) according to the manufacturer’s protocol with
maximum exposure time of 1’.
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Other assays
Tumor necrosis factor-a (TNFa), an inductor of sPLA2
expression [10], was measured using an ELISA kit hav-
ing as detection range 23-1,500 pg/mL. FFA, the pro-
ducts of sPLA2 reaction, were measured using a
colorimetric assay [20] having as detection range was 7-
1,000 μM. Surfactant Protein-A (SP-A) was measured
using an ELISA kit having as detection range 0.16/500
ng/mL [21]. These assays (Biovendor Laboratorni, Brno,
Czech Republic) had coefficients of variations ≤10%.
Proteins and urea were measured, as previously
described [22,23]. Serum urea values obtained during
the routine clinical tests in the same day of the lavage
were used to calculate the serum-to-BALF urea ratio
and obtain epithelial lining fluid (ELF) concentrations.
Biophysical study
Sixteen BALF specimens consisted of a remaining
volume ≥500 μL, beyond that used for the above-
described assays. These specimens were immediately
frozen and sent under dry ice to the biophysical labora-
tory. Total native surfactant (large plus small aggregates)
was purified by ultracentrifugation (100,000 g; 4°C; 1 h),
used in aqueous suspension and diluted with Tris buffer
(5 mM; pH 7) containing 150 mM NaCl to the final
desired phospholipids concentration, without organic
extraction. Phospholipids were measured as previously
published [24]; detection limit was 11 μg/mL.
Surfactant activity was then evaluated using captive
bubble surfactometry (CBS), as previously described
[25,26]. In detail, CBS chamber was thermostated at 37°
C and contained 5mM Tris-HCl (pH 7), 150 mM NaCl,
and 10% sucrose. After a small air bubble (0.035-0.040
cm3) was formed, approximately 150 nL of surfactant
(10mg/mL) was deposited below the bubble surface with
a transparent capillary, as previously described [27]. Fol-
lowing the introduction of surfactant, changes in surface
tension were monitored for 5 min (initial adsorption)
from the change in the bubble shape [28]. The chamber
was then sealed and the bubble was quickly (1s)
expanded to 0.15 cm3, to record post-expansion adsorp-
tion during 5 min. Then quasi-static cycles started,
where the bubble size was first reduced and then
enlarged in a stepwise fashion. There was 1’ delay
between the four quasi-static cycles and the following
dynamic cycles. During dynamic cycles the bubble was
continuously compressed and expanded at a rate of 20
cycles/min.
All laboratory assays were performed in triplicate by
investigators blinded to the clinical data.
Clinical data
Clinical data, PRISM-III24 [29], and derived predicted
mortality were recorded. Single breath static respiratory
system compliance (Crs) was measured, just before the
lavage, under controlled ventilation, using a passive
exhalation following end-inspiratory occlusion [30]. 15’
before lavage, routine gas analysis was also performed
from an indwelling arterial line: PaO2/FiO2 and oxyge-
nation index (OI= ((mean airway pressure) x FiO2/
PaO2)) were recorded. Severity of ARDS was assessed
using the Murray’s lung injury score modified for chil-
dren [30]. Finally, length of PICU stay, duration/type of
ventilation, and duration of oxygen therapy were down-
loaded from bedside monitoring system (DIGISTAT®,
United Medical Software, Cerbaia, FI, Italy).
Statistics
Data were tested for normality with Shapiro-Wilk test,
expressed as median (interquartile range) or mean ± stan-
dard deviation, and analyzed using Mann-Whitney, Stu-
dent, c2, or Fisher test, as appropriate. Spearman (r)
correlation was also applied. Correlations were corrected
adjusting for the study group (ARDS or control), or
infants’ weight and age, using partial correlation technique
[31]: to do so, variables not normally distributed were
previously subjected to Log-transformation. Statistics was
performed using SPSS 15.0 for Windows (SPSS Inc.,
Chicago, IL, USA) and P values < 0.05 were considered to
be significant.
Results
sPLA2 and other assays in BALF
Western blotting (Figure 1) showed high concentrations
of sPLA2-IIA and -X in 100% of ARDS patients, while
Figure 1 Illustrative findings of western blotting. Results are
shown for two samples of each group, as representative. Four
isotypes are expressed and secreted in BALF of ARDS infants; a-
actinin is used as control. Lower amounts of sPLA2-IIA, -V, and -X
were present only in some of the controls, while sPLA2-IB is nearly
absent.
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high amounts of sPLA2-V and sPLA2-IB were detected
in 87% and 75% of cases, respectively. Lower amount of
sPLA2-IIA, -V, and -X were also observed in 64%, 50%,
and 78% of controls, respectively. sPLA2-IB was nearly
absent in control BALFs.
Significant differences exist between cases and controls
in terms of sPLA2 activity, phospholipids, TNFa, FFA
(Figure 2). TNFa (814 (506-2,499) vs. 287 (111-1,315) pg/
mL; P = 0.04), sPLA2 activity (430 (253-600) vs. 149
(61-387) IU/mL; P = 0.01), and FFA (4.3 (2.8-8.6) vs. 2
(0.8-4.6) μM; P = 0.026) are higher in ELF of ARDS
patients than in controls. sPLA2/SP-A ratio is also higher
in ARDS patients, although it does not reach significance
(22 ± 30 vs. 11.3 ± 6 IU/ng; P = 0.29). Conversely, the
total amount of phospholipids is lower in ELF of ARDS
patients than in controls (76.5 (54-100) vs. 1,094 (536-
2,907) μg/mL; P = 0.0001). Total ELF proteins were higher
in ARDS patients (22 (10-29.6) mg/mL) than in controls
(5.9 (4.3-25.3); P = 0.013).
No significant differences were found between direct
and indirect ARDS in terms of ELF TNFa (800 (500-
3,220) vs. 828 (462-2,203) pg/mL; P = 0.070), sPLA2
(323 (243-608) vs. 482 (261-580) IU/mL; P = 0.970),
FFA (3.3 (1.6-8.8) vs. 4.8 (3.8-8.6) mM; P = 0.4), total
phospholipids (92.5 (62-120.5) vs. 76.5 (45-82) μg/mL; P
= 0.413), and total proteins (25 (13-65.6) vs. 15 (10-29)
mg/mL; P = 0.288).
Biochemical and biophysical effect of sPLA2
Figures 3 and 4 describe the different interfacial beha-
vior when comparing surfactant from cases and controls
in CBS; both illustrative cases and grouped data are pre-
sented. Figure 3 shows kinetics of adsorption/reorgani-
zation of surfactant into an expanded bubble, after post-
expansion adsorption from two illustrative samples
(Panel A). ARDS samples do not reach the same low
surface tension of control samples, indicating that sur-
factant from cases exhibits a deficient adsorption and
reorganization upon reaching the air-bubble surface.
Minimum surface tension (g) reached by surfactant is
higher in ARDS patients then in controls (45.5 ± 4.7 vs.
40 ± 4.5 mN/m; P = 0.04; Panel B).
Figure 4 shows the compression-expansion tension-
area isotherms of illustrative ARDS (Panel A) and con-
trol (Panel B) samples subjected to dynamic cycling in
CBS (20 cycles/min). Control sample reach g = approxi-
mately 20 mN/m, while ARDS sample does not reach
values < 30 mN/m. Grouped data show that g is higher
in ARDS patients then in controls (25.6 ± 6.1 vs. 18 ±
1.8 mN/m; P = 0.034; Panel C). Maximum surface ten-
sion (δ) is similar between cases and controls (54 ± 2.5
vs. 54.7 ± 2.6; P = 0.491; Panel D). Relative area, which
is the compression rate needed to reach g is slightly
lower in cases than in controls (0.5 ± 0.04 vs. 0.6 ± 0.04;
P = 0.5; Panel E).
Figure 5 shows correlations between sPLA2 activity
and biochemical or biophysical consequences in terms
of reaction products (FFA) and minimum surface ten-
sion, respectively. There are significant correlations in
ELF between sPLA2 and FFA (r = 0.823; P < 0.001) and
between sPLA2 and g (r = 0.55; P < 0.028). A significant
correlation between sPLA2 and TNFa has also been
found (r = 0.6; P < 0.001). These relationships remained
significant when adjusting for infants’ age and weight
(partial correlation coefficients sPLA2-FFA: 0.88, P <
0.001; sPLA2-g: 0.66, P = 0.005; sPLA2-TNFa: 0.57, P =
0.001). Analogous results were obtained adjusting for
the study group (data not shown).
Table 2 reports similar significant correlations
between FFA, g, and lung mechanics and clinical sever-
ity. These correlations remained significant when adjust-
ing for the study group (data not shown).
Clinical outcomes
Significant correlations between sPLA2 activity and clin-
ical outcomes are shown in Figure 6 and remained sig-
nificant after adjusting for infants’ weight and age.
Details were as follows: sPLA2 activity and PICU stay (r
= 0.54; P = 0.001; adj-P = 0.001), sPLA2 and PRISM-
III24 (r = 0.79; P < 0.001; adj-P < 0.001), sPLA2 and
duration of mechanical ventilation (r = 0.53; P = 0.002;
adj-P < 0.001), sPLA2 and duration of oxygen therapy
(r = 0.54; P = 0.001; adj-P = 0.001). Similar correlation
exists between sPLA2 and predicted mortality rate
derived from PRISM-III24 (r = 0.76; P < 0.001; adj-P <
0.001). These correlations remained significant when
adjusting for study group (data not shown). No other
correlations were found.
Eight ARDS patients (30%) needed rescue HFOV and
they presented significantly higher sPLA2 activity in ELF
(597 (367-1,476) IU/mL), as compared to ARDS patients
remaining under conventional ventilation (321 (152-509)
IU/mL; P = 0.02). g also resulted slightly higher in
ARDS patients needing HFOV than in those conven-
tionally ventilated (25 ± 6.8 vs. 21 ± 5.3 mN/m; P =
0.47), although this does not reach significance.
Discussion
This study shows that alveolar sPLA2 plays a role in
pediatric ARDS. sPLA2 activity consisted of four distinct
enzyme subtypes and may cause biochemical and bio-
physical consequences. In fact, sPLA2 activity seems to
be downstream correlated with clinical severity and
some clinical outcomes. This study partially expands the
knowledge accumulated on adults and, for the first time,
provides specific data for pediatric ARDS in this regard.
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Figure 2 sPLA2 and molecules related to its activity or expression in epithelial lining fluids. Pooled data from cases and controls. TNFa
(Panel A; *P = 0.04), sPLA2 total activity (Panel B; §P = 0.01), FFA (Panel C; #P = 0.026) and total phospholipids (Panel D; ♥P = 0.0001) are
significantly different between ARDS and controls. Panel E shows sPLA2/SP-A ratio and Panel F shows results presented in the other panels,
normalized as unit-free ARDS patients/controls ratio. Data are shown as medians or mean, as appropriate; T-bars represent standard error. ARDS:
acute respiratory distress syndrome; FFA: free fatty acids; SP-A: Surfactant protein A; sPLA2: secretory phospholipase A2; TNFa: tumor necrosis
factor-a.
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Figure 3 Biophysical behavior of surfactant in terms of minimum surface tension (g) reached by BALF samples, after 5 min of post-
expansion adsorption in captive bubble surfactometry. Panel A: Illustrative results for one sample of each group: control (black full circles)
and ARDS infants (open circles). Panel B: pooled data from cases and controls: mean minimum surface tension (g) is higher in ARDS than in
controls (*P = 0.04). Data are shown as mean. T-bars represent standard error.
Figure 4 Biophysical behavior of surfactant after repeated compression-expansion dynamic cycles in captive bubble surfactometry.
Panels A and B: illustrative results for one sample of each group in terms of minimum surface tension (g). Dynamic cycling of control (A) and
ARDS infants (B): cycle number 1, 10, and 20 are depicted by black and grey circles and grey triangles, respectively. Panel C, D, and E:
pooled data from cases and controls, after 20 compression-expansion dynamic cycles. Panel C shows mean minimum surface tension (g) to
be higher in ARDS than in controls (*P = 0.034); panels D shows mean maximum surface tension (δ); panel E shows relative area, that is the
proportion of compression needed to reach g at the end of the 20th dynamic cycle. Data are shown as mean. T-bars represent standard
error.
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sPLA2 activity and identification
sPLA2 activity is increased, as well as TNFa [10], and FFA,
the product of reaction catalyzed by sPLA2. As previously
reported [12], a significant correlation exists between
TNFa and sPLA2, confirming the role of TNFa as enhan-
cer of sPLA2 expression. [10] This leads to relevant conse-
quences in terms of biochemical and biophysical effects.
Total amount of phospholipids is also reduced in BALF of
ARDS patients, although a qualitative alteration of the
phosphilipid pool is also likely to occur (see below). Adult
ARDS patients have lower levels of SP-A [21] and this pro-
tein is known to directly inhibit sPLA2-IIA [32,33]. SP-A
binds sPLA2 through a direct protein-protein interaction,
thus it has been expressed as a ratio [32,33]. Our data
seem to suggest that SP-A could be relatively lacking and
that the interaction between sPLA2 and SP-A could play a
role also in pediatric ARDS patients. However, the differ-
ence in sPLA2/SP-A ratio between cases and controls is
not statistically significant, possibly due to our small popu-
lation size: claryfing the role of SP-A is worth to be done
with a specific study. In fact, commercially available
surfactants do not have SP-A and this may account for the
variable efficacy of surfactant replacement therapy. [9]
sPLA2-IIA, -V, and -X are highly expressed in nearly all
infants and secreted into the alveoli. These subtypes are
also detected, although in lower amount, in some controls
and this is consistent with animal data showing their
expression in total lung extracts, as sPLA2-IIA is produced
from various circulating cells [2] and sPLA2-V and -X
from airway epithelial cells [34]. Presence of some amount
of sPLA2 isotypes may be due to their physiologic roles as
anti-infective molecules [2] or to a certain degree of
inflammation. In fact, our controls were intubated infants
and some ventilation-induced inflammation is unavoid-
able. While the importance of sPLA2-IIA had been already
highlighted in ARDS [5,6], sPLA2-V and -X were only
suspected to play a role, given the animal data available so
far. These studies showed that sPLA2-V expression in
mice lung is associated with surfactant hydrolysis [35] and
gene targeted mice lacking sPLA2-V presented a milder
form of acute lung injury with lower inflammation [36].
Similarly, sPLA2-X can efficiently hydrolyse surfactant
phospholipids in vitro and this activity is also inhibited by
SP-A [2,33]. Our findings in human infants with ARDS
seem to confirm a role for sPLA2-V and -X. A propeptide
of sPLA2-IB had been detected in serum of adult ARDS
patients but not in controls [37]: this is consistent with
our data showing presence of sPLA2-IB in 75% of patients.
Given the widespread tissue distribution of sPLA2-IB [1,2],
it is possible that this subtype arrives to the lung after
production elsewhere or from circulating inflammatory
cells reaching the lung. Alternatively, sPLA2-IB may be
locally triggered by sPLA2-IIA, since a specific cross-talk
exists between the two subtypes [38]. These data are
relevant, as many sPLA2 inhibitors are now under
advanced investigation and carry different inhibitory
potency against the four described subtypes [11].
Figure 5 Biochemical and biophysical correlations of sPLA2
activity in epithelial lining fluid. Lines are drawn by the minimum
square root method corresponding to the following equations: A (Y
= 11*x -185); B (y = 0.005*x +17.5).
Table 2 Correlation between free fatty acids (FFA),
surface tension (g), and lung mechanics and clinical
severity.
FFA g
r P Adj-P r P Adj-P
Crs -0.46 0.009 0.011 -0.54 0.03 0.047
Murray’s score 0.643 <0.001 0.004 0.57 0.021 0.035
OI 0.45 0.008 0.021 0.53 0.036 0.045
Lung mechanics are described by Crs, while clinical severity by Murray’s score
and OI. Spearman correlation coefficient (r) with its significance p-value. Adj-p
is the p-value adjusted for infants’ weight and age, using partial correlation
technique.
g: minimum surface tension; Crs: static compliance of the respiratory system;
FFA: free fatty acids; OI: oxygenation index.
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Biochemical and biophysical effect of sPLA2
There is a deficient adsorption and re-organization of
material into the air/water interface leading to higher sur-
face tension in ARDS infants, both after the post-expan-
sion adsorption and during the breathing-mimicking,
compression-expansion dynamic cycling. The different
shape of the loops is also consistent with these data. Since
CBS was carried out at the same phospholipid concentra-
tion, it is the quality of surfactant that seems to be affected
in ARDS. This qualitative alteration has been already
described in adult ARDS patients [39] and may be related
to the activity of the various sPLA2 subclasses secreted
into the alveoli. Concomitantly, the presence of other
inflammatory proteins and higher amounts of neutral
lipids may also be partially responsible for surfactant
alteration [40,41].
Increased surface tension at the end of the compression
has already been described in adult ARDS and supposed
to cause atelectasis and lung collapse [42]. This is con-
firmed by our findings, as minimal surface tension is
significantly correlated to Crs and to gas exchange impair-
ment. The latter two have been linked with sPLA2 in ani-
mal studies and in adults with ARDS [3-6]. Interestingly,
not only surface tension, but also FFA, correlate with
these physiopathologic variables. It has been demonstrated
that the two products of sPLA2 reaction, lysophospholi-
pids and FFA, are potent inhibitors of surfactant biophysi-
cal activity [42]. Conversely, FFA are precursors of various
proinflammatory mediators: thus, the effect on lung com-
pliance and oxygenation may be not only due to the direct
lypolitic activity of sPLA2 on surfactant phospholipids,
but also to lysophospholipids and FFA inhibiting the
Figure 6 Correlations with clinical outcomes. Epithelial lining fluid sPLA2 activity and correlation with PICU length of stay (A), PRISM-III24 score
(B), duration of mechanical ventilation (C), and oxygen therapy (D). Lines are regression lines drawn by the minimum square root method: A (y
= 0.01*x +8.6); B (Y = 0.01*x +4.1); C (y = 0.01*x +3); D (y = 0.01*x +5.2). MV: mechanical ventilation; PICU: Pediatric intensive care unit; sPLA2:
secretory phospholipase A2.
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remaining surfactant and to the additional contribution of
other FFA-derived inflammatory molecules. Consistently,
the Murray’s lung injury score, that globally describe the
clinical severity (taking into accout Crs, oxygenation defi-
cit, and other variables), also correlates with both surface
tension and FFA. We must admit that correlations shown
in Table 2 are statistically significant but lower than
others, thus a strong and direct relationship cannot be
assumed just from these findings. Given the biological
background, a link is likely to exist between the analyzed
variables, but it is also possible that other factors are
involved in these relationships influencing the results
[40,41].
Minimal surface tension produced upon cycling of
control samples under our experimental conditions are
higher than those required to stabilize the lungs. In
principle, a good functional surfactant film should pro-
duce tensions <5 mN/m when compressed in CBS [43].
It is possible that sampled surfactants are particularly
enriched in material from the upper airways, with more
limited surface activity that surfactant freshly secreted
by the alveolar epithelium. It is also possible that
mechanical ventilation might induce an inhibitory effect,
both in controls and in ARDS patients, affecting the
minimal tension reached by the relatively diluted con-
centrations of surfactant tested here. Finally, it is also
conceivable that differences in minimal tensions
between controls and ARDS patients could be maxi-
mized if tested at higher surfactant concentrations.
Unfortunately, the limited sample volume available from
infants prevented the assay at concentrations >10 mg/
mL. Anyway, all samples were assessed at equivalent
phospholipid concentrations, indicating that the differ-
ences found between controls and ARDS patients are
indicative of an actual alteration of surfactant function.
Clinical outcomes
Raised sPLA2 activity, through the increment in inflamma-
tion and surface tension that impairs lung mechanics and
oxygenation, might finally have relevant clinical conse-
quences. In fact, as secondary study aim, we found sPLA2
activity to be significantly correlated with PICU stay, dura-
tion of mechanical ventilation, and oxygen therapy. Our
population mortality is consistent with other reports [7].
Since pediatric ARDS has a relatively low incidence and
mortality, this latter is not a feasible clinical endpoint,
while shorter respiratory support is an accepted alternative
outcome resulting from decreasing inflammation [7]. Simi-
larly, PICU stay is an alternative, as it may impact on
mortality through the increased risk of nosocomial
infections and on the general burden of care. sPLA2 activ-
ity is also correlated with the PRISM-III24 and its predicted
mortality. Similar correlation with predicted mortality was
described in adults using a different score commonly
applied in adult critical care [6]. About 30% to 40% of
PICUs worldwide are using HFOV as rescue method for
respiratory support in children unresponding to conven-
tional ventilation [7] and since we have a strict protocol for
rescue HFOV, we were able to analyze this as a secondary
additional outcome. Consistently with the other findings,
babies needing HFOV turned out to have higher sPLA2
levels. Rescue HFOV may use higher Pāw to recruit alveoli
in more stiff and collapsed lungs; thus, it seems logical that
patients with higher sPLA2 activity have more diseased
lungs and require such technique to be ventilated.
There are some study limitations and some questions
still to be answered. Ours is a relatively small population
and larger cohorts may be required to accurately study
the correlation between sPLA2 and clinical outcomes.
Scarce data are available about lung function of ARDS
surviving-children [44], although a spectrum of different
consequences is conceivable. A larger study is required
to clarify if sPLA2 over-activity may predispose to
chronic lung diseases in ARDS survivors or if there is
any alteration of pulmonary function test later on.
Given the small population size and the descriptive
nature of the study, limited conclusions can be general-
ized to other infants: other confounding factors should
be taken into account. In detail, genomic population
surveys including sPLA2 and other genes must be per-
formed in order to verify the predisposition for ARDS.
Our international project [13] already included a genetic
study on the sPLA2 isoforms polymorphisms: this study
is still in progress and provisional results have been pre-
sented elsewhere [45].
Our patients have been sampled only once at the
study enrolment and we cannot provide data during the
ARDS course. Around 58% of our cases are represented
by infection-related ARDS: different triggering condi-
tions might influence some results.
Moreover, while the interaction between SP-A and
sPLA2-IIA is known [32,33], there are no data about the
other sPLA2 isoforms. Recently, Surfactant Protein-B (SP-
B) resulted able to inhibit phospholipid hidrolysis induced
by both sPLA2-IB and -IIA [46]. This effect is not due to a
direct enzymatic inhibition and a synergistic effect
between different (hydrophobic and hydrophilic) surfac-
tant proteins has been hypothesized [46]. The interaction
between surfactant proteins and distinct sPLA2 deserves
to be studied, as inflammation and clinical consequences
could be more strictly related to the complex biological
interactions between various bioactive molecules, rather
than by the effect of a single one.
It would be also interesting to study serially infants
with repeated lavages during the ARDS course: this may
give clues about the progression of inflammation. It may
also indicate how sPLA2 might influence the function of
alveolar macrophages or the production and activity of
De Luca et al. Critical Care 2013, 17:R163
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different surfactant proteins. This requires a specific
study not easy to be done in such small critically ill
patients, where lavages procedures are not totally harm-
less and cell recovery is often unsatisfactory.
Finally, different subtypes profile could have relevant
consequences on clinical pictures and future treatment
approaches: we identified various sPLA2 subtypes, but we
were not able to measure their relative amount or activity.
In fact, we do not have available densitometry, and
besides, a more precise activity measurement or separation
should have been performed. This is more difficult, given
the extreme sequence similarity of sPLA2 isoforms and we
mean to work on this in a future study. Moreover, an
increased sPLA2 activity is likely to be caused by an
increased production of all (or some) isotypes. However,
we cannot exclude that there may be some protein modifi-
cations increasing enzymatic activity without increasing its
expression, but this has never been found till now, whereas
increment in some subtypes (sPLA2-IIA and -IB) has been
demonstrated in adult ARDS patients [5,6,37].
Conclusions
Total sPLA2 activity is raised in infants with ARDS and
constituted of four enzyme subtypes. sPLA2 is corre-
lated with some inflammatory mediators and surface
tension. These two are correlated in their turn with lung
compliance and oxygenation impairment. Relevant clini-
cal consequences might be caused, as sPLA2 seems cor-
related with predicted mortality rate, longer PICU stay,
mechanical ventilation, and oxygen support. These find-
ings describe sPLA2 as a potential target in infants with
ARDS.
Key messages
• sPLA2 is constituted of at least four isotypes dur-
ing pediatric ARDS.
• sPLA2 is correlated with pediatric ARDS physio-
pathology (surface tension, lung compliance, oxyge-
nation impairment).
• sPLA2 is correlated with clinical outcomes in
pediatric ARDS (predicted mortality, PICU stay,
duration of mechanical ventilation, and oxygen
therapy).
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